The End­points 100: No­var­tis gets 'poor' grade on da­ta scan­dal, Ned Sharp­less is­n't a 'wow' and that Cana­da drug im­por­ta­tion plan is a non­starter

No­var­tis’ lat­est scan­dal re­volv­ing around hid­den da­ta ma­nip­u­la­tion has be­come a cau­tion­ary tale for the bio­phar­ma in­dus­try — and one that of­fers clear guide­lines on do­ing the right thing.

That is just one of the in­evitable con­clu­sions to be reached from our lat­est sur­vey of the End­points 100, which tracks the opin­ion of a glob­al group of se­nior ex­ec­u­tives in the in­dus­try — who share some sharp ob­ser­va­tions on where we are head­ed in bio­phar­ma. 

Uni­for­mi­ty is clear­ly out when it comes to the E100, but it’s easy to see which way the wind is blow­ing for the ma­jor­i­ty of the 74 ex­ecs who par­tic­i­pat­ed in the lat­est round.

In ad­di­tion to the hot but­ton is­sues we sur­veyed the group on, we’re see­ing plen­ty of hir­ing con­tin­ue at these com­pa­nies — not un­ex­pect­ed in a field that has seen a decade of rapid growth. But while most con­tin­ue to see the fi­nan­cial en­vi­ron­ment we’re in now as a pos­i­tive — with ac­cess to cap­i­tal, a “warm” en­vi­ron­ment for M&A and good val­u­a­tions — there’s al­so been a dis­tinct re­duc­tion in the fer­vor that’s be­ing felt here.

That cool­ing en­thu­si­asm may not be un­ex­pect­ed at a time when stock val­u­a­tions for a host of play­ers have been beat­en up some — or a lot. But the fun­da­men­tals all still look rock-sol­id, for now.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER